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Abstract 
Purpose: To investigate the effect of input parameters for an inverse optimization algorithm, and dosimetrically 
evaluate and compare clinical treatment plans made by inverse and forward planning in high-dose-rate interstitial 
breast implants. 
Material and methods: By using a representative breast implant, input parameters responsible for target coverage 
and dose homogeneity were changed step-by-step, and their optimal values were determined. Then, effects of param-
eters on dosimetry of normal tissue and organs at risk were investigated. The role of dwell time modulation restriction 
was also studied. With optimal input parameters, treatment plans of forty-two patients were re-calculated using an 
inverse optimization algorithm (HIPO). Then, a pair-wise comparison between forward and inverse plans was per-
formed using dose-volume parameters. 
Results: To find a compromise between target coverage and dose homogeneity, we recommend using weight 
factors in the range of 70-90 for minimum dose, and in the range of 10-30 for maximum dose. Maximum dose value of 
120% with a weight factor of 5 is recommended for normal tissue. Dose constraints for organs at risk did not play an 
important role, and the dwell time gradient restriction had only minor effect on target dosimetry. In clinical treatment 
plans, at identical target coverage, the inverse planning significantly increased the dose conformality (COIN, 0.75 vs. 
0.69, p < 0.0001) and improved the homogeneity (DNR, 0.35 vs. 0.39, p = 0.0027), as compared to forward planning. All 
dosimetric parameters for non-target breast, ipsilateral lung, ribs, and heart were significantly better with inverse plan-
ning. The most exposed small volumes for skin were less in HIPO plans, but without statistical significance. Volume 
irradiated by 5% was 173.5 cm3 in forward and 167.7 cm3 in inverse plans (p = 0.0247). 
Conclusions: By using appropriate input parameters, inverse planning can provide dosimetrically superior dose 
distributions over forward planning in interstitial breast implants. 
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Purpose 
Inverse planning algorithms have been routinely used 
in external beam therapy for intensity and volume mod-
ulated radiotherapy for several years, but in brachyther-
apy (BT), it cannot be considered as a standard planning 
method yet. In BT, the classical dosimetry systems played 
an important role in standardizing the treatments and 
were developed for low-dose-rate (LDR) sources. How-
ever, the introduction of high-dose-rate (HDR) stepping 
source technique opened new possibilities in clinical do-
simetry. Furthermore, the introduction of cross-sectional 
imaging and 3D target volume definition in BT required 
new planning approaches. Forward optimization is now 
regularly used for BT planning, and the most accepted 
methods are the geometrical (GO) and graphical optimi-
zations (GRO), which can provide clinically acceptable 
dose distributions for breast implants [1,2,3,4]. During 
GO, there is no need for defining dose points, because 
dwell positions themselves serve as reference dose points 
for optimization. After GO, the dwell time at any dwell 
position is inversely proportional to the dose delivered 
by other dwell positions, resulting in homogeneous dose 
distribution. If the catheters geometrically cover the tar-
get volume properly, the planning target volume (PTV) is 
encompassed by the reference isodose surface. In case of 
possible geometrical miss of the catheters, an underdosed 
region can develop in the PTV, which can be decreased 
using the GRO. With the drag-and-drop method, an iso-
dose line can be shifted into a desired position on the CT 
image with the cursor on the screen. However, it must 
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be remembered that with improving target coverage, 
the dose homogeneity deteriorates. In BT, the coverage 
is generally characterized by the V100 (percentage of PTV 
receiving at least 100% of the prescribed dose [PD]), while 
the dose homogeneity is considered as the DNR (dose 
non-uniformity ratio). The latter is the ratio of volumes 
irradiated by 1.5 times the PD and the PD. To make an 
optimal plan, many steps must be occasionally repeated 
during the planning process, with continuous evaluation 
of the dose-volume histogram (DVH) parameters. Since 
the target coverage and dose homogeneity always change 
in the opposite direction, there is a big challenge for the 
planner to meet both conditions with a compromise. 
This requires repetitive dose calculations, which can be 
time-consuming. On the contrary, during inverse optimi-
zation, all dosimetric requirements (dose coverage, dose 
homogeneity, organs at risk [OARs] protection) are simul-
taneously and automatically considered. Inverse optimi-
zation always requires cross-sectional imaging, since it is 
anatomy-based, and the 3D volume definitions are its pre-
conditions. The two most frequently used algorithms in 
BT are the HIPO (hybrid inverse planning optimization) 
[5] and IPSA (inverse planning simulated annealing) [6]. 
In BT, apart from prostate cancer, the integration of 
inverse planning into clinical routine has not been accom-
plished so far. In the literature, there are reports on the use 
of inverse planning for cervix cancer [7,8,9,10,11,12,13], 
vaginal irradiation [14,15], and head and neck brachyther-
apy [16,17]. For breast cancer, the available information 
is scarce. Among partial breast irradiation techniques, 
interstitial brachytherapy has the longest patients’ fol-
low-up and the highest level of evidence as an alternative 
treatment option to whole breast irradiation [18,19,20]. 
Based on our experience with forward planning in breast 
BT, in this work, we performed a detailed investigation 
about the feasibility of inverse planning in interstitial 
HDR breast implants and compared its efficacy with con-
ventional forward planning regarding target dosimetry 
and protection of OARs. 
Material and methods 
First, a representative case was selected to investigate 
the effect of optimization parameters on target dosimetry 
during inverse optimization. The Oncentra Brachy v.4.5.3 
planning system (Elekta Brachytherapy, Veenendaal, The 
Netherlands) was used for both forward and inverse opti-
mizations. The HIPO implemented in Oncentra Brachy is 
based on dose-volume parameters defined as minimum 
(MinValue) and maximum (MaxValue) dose limits for tar-
gets [5,21], and for OARs, only maximum dose limits are 
considered. Based on these dose limits, HIPO calculates 
a corresponding objective function, and with an impor-
tance factor or penalty (MinWeight, MaxWeight) defined 
by the user, HIPO calculates the total objective function, 
which is then considered for the optimization. The total ob-
jective function is subsequently calculated as the weighted 
sum (aggregation) of all individual objective functions. 
The results of optimization are the source dwell times. 
Using HIPO, the effects of different weight factors 
and dwell time modulation on target dosimetry were in-
vestigated in detail and subsequently, their optimal val-
ues were defined. As a first step, the minimum weight 
(MinWeight) was changed between 0 and 100 in steps 
of 10, and its effect on V100 and DNR was calculated at 
various dose homogeneity. Then, the maximum weight 
(MaxWeight) was changed between 0 and 100 in steps of 
10, and V100 and DNR were calculated at different target 
coverage. Afterwards, the optimization on normal tissue 
and OARs was studied. For normal tissue, the role of 
maximum dose value and its weight were examined. The 
objectives used for an OAR situated close to and far from 
the PTV (skin and rib, respectively) were also changed, 
and subsequent target dosimetry was assessed. The tar-
get volume was adjacent to skin and a few cm away from 
the rib. 
HIPO includes an option for modulating dwell times 
in neighboring dwell positions, which is called dwell time 
gradient restriction (DTGR). The DTGR parameter takes 
value between 0.0 and 1.0. At value of 0.0, there is no 
restriction, and large fluctuations between neighboring 
dwell times can develop. When maximal value is applied 
(DTGR = 1.0), the resulting distribution of dwell times 
in catheters will be smooth, similar to GO. The effect of 
modulation of neighboring dwell times on target cover-
age and dose homogeneity in HIPO was also investigat-
ed. The parameter of DTGR was changed between 0.0 to 
1.0 in steps of 0.1, and V100 and DNR were calculated. 
In the second part of the study, treatment plans of for-
ty-two patients with early stage breast cancer who were 
treated with accelerated partial breast irradiation using 
multicatheter interstitial brachytherapy were selected. 
The patient selection and target volume definition were 
based on the GEC-ESTRO recommendations [22,23]. Us-
ing the optimal input parameters determined in the first 
part of our study, competing treatment plans were made 
with HIPO, and they were compared with the original 
forward plans. 
Implantation and forward planning 
Our implantation technique was based on two CT 
imaging. The first one was used for planning the posi-
tion of catheters, and then the treatment planning was 
completed by a second imaging performed after the im-
plantation. First, lumpectomy cavity, PTV, and organs 
at risk were delineated and then, the catheters were 
reconstructed using the CT information. After that, the 
source dwell positions were activated inside the PTV 
with 0 margin, and geometrical optimization was per-
formed. Basal dose points were created in the central 
plane and after normalization, an isodose line was se-
lected for dose prescription, so that the target coverage 
be at least 90%. The f-factor used for dose prescription 
ranged between 0.75 and 0.90, corresponding to isod-
ose level of 75% and 90%. At the same time, a proper 
dose homogeneity had to be maintained with the DNR 
≤ 0.35. At conflicting values, the target volume coverage 
was prioritized. In case when the target coverage was 
not sufficient, graphical optimization was applied to 
improve the dose distribution locally in the underdosed 
regions. The prescribed dose (PD) was 7 × 4.3 Gy. This 
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method is called conventional or forward planning, and 
referred as GO + GRO. The catheters were implanted 
into the breast in a triangular pattern, with a separation 
of 1.3 cm. The source step size was 2.5 mm, the first/last 
source position in the catheters was always at least 5 mm 
from the skin surface. The resolution of calculation ma-
trix was 1 mm. 
Inverse planning 
Retrospectively, for each patient, a plan with inverse 
optimization (HIPO) was made using the same CT im-
ages and contours used in forward planning. The input 
parameters in HIPO that were used included: for PTV – 
MinWeight = 75, MinValue = 100, MaxWeight = 25, and 
MaxValue = 150, and for normal tissue – MaxWeight 
= 5 and MaxValue = 120. Normal tissue, which is always 
mandatory for the optimization, is considered as all tis-
sues surrounding the PTV, excluding any other OARs. 
For other OARs, no objectives were applied here. The 
MinValue and MaxValue were related to the PD as per-
centages. The value for DTGR parameter was selected to 
be 0.2. The active source positions were inside the PTV, 
similarly to GO + GRO. 
Competing plans were assessed and compared with 
dose-volume parameters, such as relative volumes receiv-
ing a percentage of PD (e.g., V100, V90, V50) and relative 
doses in percentage of the PD to small absolute volumes 
(e.g., D0.1cm3, D1cm3). Since the skin and ribs were not de-
lineated as whole organs, the V5 for skin and the V50 for 
ribs were given as absolute value in cm3. The dose ho-
mogeneity was described by the DNR (dose non-unifor-
mity ratio) and the conformality with COIN (conformity 
index). The COIN simultaneously considers the coverage 
of PTV and irradiation of normal tissues outside the PTV 
by the PD [24]. Descriptive statistics were used to char-
acterize the two groups of treatment plans, and the dis-
tribution of parameters was tested with Shapiro-Wilk’s 
W test regarding normality. Since most of the parameters 
were not normally distributed, non-parametric Wilcoxon 
matched-pairs test was used for all comparisons with Sta-
tistica 7.0 software (StatSoft, Inc., Tulsa, OK, USA), and 
p < 0.05 was considered statistically significant.
Results 
A representative patient with a PTV of 34 cm3 and im-
planted with 12 catheters was selected to study the effect 
of optimization parameters in HIPO. 
Target coverage and dose homogeneity 
In Figure 1, the target coverage and dose homogeneity 
are presented in the function of minimum weight at dif-
ferent homogeneity parameters. As the minimum weight 
increased, the V100 continuously improved. The larger the 
MinWeight, the higher the V100 (Figure 1A). Furthermore, 
the maximal coverage developed when the constraint for 
dose homogeneity was weak (MaxWeight = 25). When 
the homogeneity was the greatest (MaxWeight = 100), 
the coverage was less than 80%. The dependence of DNR 
on MinWeight was not monotonous (Figure 1B). As the 
MinWeight increased, the DNR decreased first and then 
slowly increased. The lowest DNR was around 0.20 but 
developed at different MinWeight depending on the 
MaxWeight. Based on the graphs in Figure 1A, the value 
for minimum weight in the range of 70-90 seemed to be 
an acceptable compromise between the target coverage 
and the dose homogeneity. 
Looking at the changes of V100 and DNR in the func-
tion of dose homogeneity parameter (MaxWeight), an 
explicit dependence was observed. Putting emphasis on 
the importance of dose homogeneity both the V100 and 
the DNR decreased (Figure 2). The DNR was the low-
est at MinWeight = 25 (Figure 2B), but the coverage was 
not acceptable at MaxWeight higher than 10. The V100 
was greatly influenced by the MinWeight and the Max-
Weight, which is shown in Figure 2A. Only low values of 
MaxWeight resulted in adequate coverage (V100 ≥ 90%), 
but the DNR was high at MaxWeight below 10. A range 
Fig. 1. Dependence of target coverage (A) and dose homogeneity (B) on the weight factor for minimum dose (MinWeight) at 
the periphery of PTV. The horizontal line shows the planning aim and the double-headed arrow indicates the range of recom-
mended values. V100 is the percentage of PTV receiving the prescribed dose, DNR is the dose non-uniformity ratio. MaxWeight 
is a weight factor controlling the dose homogeneity in the PTV
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between 10-30 was a compromise again between the tar-
get coverage and the dose homogeneity. 
Normal tissue 
The normal tissue surrounded the PTV and it was 
always obligatory to use objectives for it. Table 1 shows 
how the two input parameters (MaxValue, MaxWeight) 
affect the target coverage characterized by the V100. The 
shaded area included the coverage higher than 90%. At 
low weight factor (MaxWeight = 5), the V100 was always 
larger than 90% independently on the maximal dose val-
ue (MaxValue). If the allowed dose maximum was 120%, 
the weight factor did not influence the coverage, since 
the V100 was between 91.7% and 92.7%. The dose homo-
geneity also depended on MaxValue and MaxWeight of 
normal tissue (Table 2). In the shaded area, the DNR was 
less than 0.35. If the MaxValue was relatively low (≤ 60%) 
homogeneous dose distribution developed at any weight 
factor (DNR < 0.35). When using a low weight factor for 
maximum dose (MaxWeight = 5), the DNR was always 
low (0.30-0.31) and it did not depend on the maximum 
dose value. Summarizing the results shown in Tables 1 
and 2, the MaxValue = 120 with MaxWeight = 5 as an ob-
jective for normal tissue seemed to be the right selection 
for input parameters in inverse planning. 
Organs at risk 
With proper normal tissue dosimetry, the dose to 
OARs can be kept low. If an OAR was not used directly 
during dose optimization, it would be a part of normal 
tissue and the dose objectives to normal tissue would im-
plicitly apply to that as well. For example, if the target is 
superficially located and the PTV touches the skin defined 
as a 5 mm layer from body surface, the dose objective set 
up for normal tissue will govern the skin dosimetry. This 
is demonstrated in Table 3, since the coverage was nearly 
identical at all weight factors and change of the DNR was 
also very small. When the maximum dose to skin was in- 
creased from 40% to 120% at maximum weight factor 
(MaxWeigh = 100), the coverage improved slightly and 
the homogeneity marginally deteriorated, but the change 
of V100 and DNR was less than 1% (Table 4). In this anal-
ysis, we used MaxValue = 120 and MaxWeight = 5 for 
normal tissue. 
Fig. 2. Dependence of target coverage (A) and dose homogeneity (B) on the weight factor for maximum dose (MaxWeight) in 
the PTV. The horizontal line shows the planning aim and the double-headed arrow indicates the range of recommended values. 
V100 is the percentage of the PTV receiving the prescribed dose, DNR is the dose non-uniformity ratio. MinWeight is a weight 
factor controlling the target coverage through minimum dose at the periphery of the PTV
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Table 1. Effect of MaxValue and MaxWeight 
parameters of normal tissue on V100 (%)
Max 
Value 
MaxWeight 
5 25 50 75 100 
20 90.6 82.1 65.2 46.6 28.3 
40 90.6 82.2 67.1 54.6 47.3 
60 90.8 84.8 77.6 72.0 68.3 
80 91.6 89.4 86.3 84.1 82.7 
100 92.1 91.7 90.8 89.9 89.4 
120 92.7 92.7 92.2 92.0 91.7 
V100 – percentage of the PTV receiving the prescribed dose 
Table 2. Effect of MaxValue and MaxWeight 
parameters of normal tissue on DNR 
Max 
Value 
MaxWeight 
5 25 50 75 100 
20 0.30 0.33 0.27 0.26 0.27 
40 0.31 0.33 0.28 0.26 0.28 
60 0.30 0.34 0.33 0.31 0.31 
80 0.31 0.36 0.36 0.36 0.36 
100 0.30 0.36 0.37 0.37 0.37 
120 0.30 0.36 0.36 0.36 0.37 
DNR – dose non-uniformity ratio 
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Dwell time gradient restriction (DTGR) 
Table 5 shows the effects of DTGR on target coverage 
and dose homogeneity. When no constraint was used for 
neighboring dwell times (DTGR = 0.0), the DNR was the 
lowest (0.341) and the V100 the highest (93.7). From 
the data, it can be observed that in the function of DTGR, 
the variation of both parameters was small, less than 
1% for the V100 and less than 5% for the DNR. 
Patient dosimetry 
The mean volume of lumpectomy cavity and PTV was 
10.7 cm3 (range, 3.5-37.0 cm3) and 56.7 cm3 (range, 26.6-
173.6 cm3), respectively. Twenty-seven patients (64%) 
had left-sided and fifteen (36%) right-sided lesion. In sev-
en cases (17%), the PTV was close to and in eight cases 
(19%) far from the skin. Median 13 catheters were im-
planted into the breast, with a range between 7 and 28. 
Table 6 includes dosimetric parameters for treatment 
plans made by forward (GO + GRO) and inverse (HIPO) 
planning for forty-two patients. The basis of comparison 
was the same target coverage. Both, the mean V100 and 
D90 were nearly identical for the two groups. But the con-
formality and the homogeneity was also better with the 
inverse planning. The mean COIN increased from 0.69 to 
0.75 (p < 0.0001) and the DNR decreased from 0.39 to 0.35 
(p < 0.0027). The volume irradiated by the PD was sig-
nificantly smaller in the inverse plans (63.6 cm3 vs. 67.5 
cm3, p < 0.0001). The non-target breast (ipsilateral breast 
excluding the PTV) received significantly less dose in the 
HIPO plans, and the same applied for the ipsilateral lung. 
The mean lung dose (MLD) was 8% less in HIPO and in 
the other three parameters (D0.1cm3, D1cm3, V5), there was 
a 5% decrease as well. Although, the doses to the most 
exposed 0.1 cm3 and 1 cm3 of skin were less with inverse 
planning, the difference was not significant. But the abso-
lute volume irradiated by low-dose (5%) was 5.8 cm3 less 
with HIPO (p < 0.0001). Regarding the dose to ribs, the 
HIPO was superior with significant less doses (D0.1cm3, 
D1cm3), and the volume irradiated by half of the PD (V50) 
was also less compared to forward planning (1.7% vs. 
1.8%, p = 0.0247). We noted that the reference isodose line 
never reached the ribs in any HIPO plan meaning that the 
maximum dose was always less than the PD, and in for-
ward plans, we observed only one case out of forty-two 
patients where volume of 0.1 cm3 received the PD. Twen-
ty-seven patients had left-sided cancer, and looking at the 
heart dosimetry, the superiority of inverse over forward 
planning could be seen. The mean heart dose was 8% less, 
and in HIPO plans, we observed not only lower doses to 
most exposed small volumes (0.1 cm3, 1 cm3), but also 
smaller volumes irradiated by low-dose (5%). The amount 
of decrease in heart parameters ranged between 8-12%, 
with always statistical significance. The dose to contralat-
eral breast and lung was always small, with no significant 
differences between the two planning techniques. 
Discussion 
Inverse planning has been intensively used in exter-
nal beam radiotherapy at least for a decade to optimize 
Table 3. Effect of weight factor of maximum dose 
to skin on target coverage and dose homogene-
ity (MaxValue = 120) 
MaxWeight V100 DNR 
0.001 92.66 0.300 
1 92.66 0.302 
10 92.67 0.304 
20 92.59 0.300 
40 92.54 0.303 
60 92.54 0.303 
80 92.53 0.307 
100 92.55 0.308 
V100 – percentage of the PTV receiving the prescribed dose, DNR – dose non-uni-
formity ratio 
Table 4. Effect of maximum dose to skin on tar-
get coverage and dose homogeneity (MaxWeight 
= 100) 
MaxValue V100 DNR 
40 91.67 0.304 
60 92.16 0.304 
80 92.49 0.305 
100 92.55 0.306 
120 92.55 0.307 
V100 – percentage of the PTV receiving the prescribed dose, DNR – dose non-uni-
formity ratio 
Table 5. Effect of dwell time gradient restriction 
(DTGR) on target coverage and dose homogeneity 
DTGR V100 DNR 
0.0 93.7 0.341 
0.1 93.4 0.354 
0.2 93.3 0.358 
0.3 93.1 0.355 
0.4 93.2 0.354 
0.5 93.2 0.354 
0.6 93.2 0.353 
0.7 93.2 0.356 
0.8 93.2 0.355 
0.9 93.2 0.357 
1.0 93.2 0.359 
V100 – percentage of the PTV receiving the prescribed dose, DNR – dose non-uni-
formity ratio 
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the dose distribution for state-of-the-art dose delivery 
techniques, such as intensity modulated radiation ther-
apy and volume modulated arc therapy. However, in 
brachytherapy, it is still not routinely used for various 
treatment sites, except for the prostate. In clinical prac-
tice in both LDR and HDR prostate BT, optimal positions 
of radioactive sources are determined with inverse plan-
ning for no less than two decades, considering surface 
and volumetric dose constraints in addition to dose limits 
to urethra and rectum [6,21,25,26,27,28,29,30,31]. The role 
of inverse planning in gynecological BT is also studied in 
the literature. Trnková et al. [7] analyzed the feasibility of 
inverse planning algorithm (HIPO) for image-guided cer-
vical cancer brachytherapy. Ten patients treated with in-
tracavitary and another ten with combined intracavitary/
interstitial techniques were planned with manual and in-
verse optimization. They found that HIPO was feasible 
for improving the therapeutic ratio and limiting the sub-
stantial high-dose regions around the needles; therefore, 
it was introduced into their clinical practice. The same 
group made a comparison between manual and inverse 
plans in HDR intracavitary/interstitial cervical cancer 
brachytherapy using data of 20 patients [8]. They found 
that HIPO produced clinically acceptable treatment plans 
and enabled the reduction of high-dose regions in the 
immediate vicinity of the target volume. Compared to 
Table 6. Comparison of patient dosimetry between treatment plans made by forward (GO + GRO) and inverse 
(HIPO) optimization techniques for 42 patients with mean ± standard deviation 
GO + GRO HIPO Difference# P-value 
PTV 
V100 (%) 91.2 ±2.43 91.4 ±2.48 0.2 0.9111 
D90 (%) 101.6 ±4.89 102.0 ±4.21 0.4 0.2914 
COIN 0.69 ±0.06 0.75 ±0.07 0.06 < 0.0001 
Implant 
DNR 0.39 ±0.07 0.35 ±0.05 –0.04 0.0027 
Non-target breast 
V100 (%) 2.2 ±1.77 1.5 ±0.94 –0.7 < 0.0001 
V50 (%) 13.0 ±8.46 12.0 ±7.65 –1.0 < 0.0001 
V25 (%) 32.0 ±15.22 30.5 ±14.56 –1.5 < 0.0001 
Ipsilateral lung 
MLD (%) 5.3 ±2.18 4.9 ±1.63 –0.4 < 0.0001 
D0.1cm3 (%) 42.9 ±13.99 40.6 ±12.98 –2.3 < 0.0001 
D1cm3 (%) 37.7 ±12.61 35.7 ±11.78 –2.0 < 0.0001 
V5 (%) 31.9 ±10.29 30.3 ±10.11 –1.6 < 0.0001 
Skin 
D0.1cm3 (%) 76.1 ±30.03 73.8 ±30.39 –2.3 0.1027 
D1cm3 (%) 59.1 ±19.82 57.5 ±19.65 –1.6 0.1633 
V5 (cm
3) 173.5 ±47.65 167.7 ±45.75 –5.8 < 0.0001 
Ribs 
D0.1cm3 (%) 56.6 ±19.21 52.1 ±18.82 –4.5 < 0.0001 
D1cm3 (%) 44.8 ±16.73 41.7 ±16.76 –3.1 < 0.0001 
V50 (cm
3) 1.8 ±2.87 1.7 ±3.15 –0.1 0.0247 
Heart* 
MHD (%) 3.9 ±1.79 3.6 ±1.75 –0.3 < 0.0001 
D0.1cm3 (%) 22.0 ±11.86 19.4 ±11.14 –2.6 0.0016 
D1cm3 (%) 18.2 ±10.06 16.6 ±9.77 –1.6 0.0002 
V5 (%) 25.8 ±17.89 23.7 ±17.95 –2.1 0.0008 
Contralateral breast 
D0.1cm3 (%) 4.3 ±2.9 3.8 ±2.55 –0.5 0.5165 
D1cm3 (%) 2.9 ±1.79 2.6 ±1.68 –0.3 0.1976 
Contralateral lung 
D0.1cm3 (%) 4.9 ±2.81 5.2 ±2.72 0.3 0.3131 
D1cm3 (%) 3.5 ±1.82 3.5 ±1.92 0.0 0.9739 
GO – geometrical optimization, GRO – graphical optimization, HIPO – hybrid inverse planning optimization; *only for left-sided lesions (27 patients), 
#HIPO – (GO + GRO) 
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IPSA, HIPO considered the current clinical experience 
gained from manual treatment planning. Other authors 
also found inverse planning feasible for cervical cancer 
BT [9,10,11,12,31]. Inverse planning can offer good spar-
ing of critical structures without compromising the target 
coverage [9]. Moreover, IPSA significantly reduces over-
all treatment planning time with improved reduction of 
doses to the OARs, as compared with a volume-based op-
timization treatment planning method [12]. Matias et al. 
[11] provided a fine class solution of HIPO, demonstrating 
comparable results in relation to graphical optimization 
regarding both dosimetric and radiobiological endpoints. 
Kannan et al. [10] found that IPSA significantly improved 
the target volume coverage compared with manual plan-
ning. Inverse planning in vaginal BT performed with 
multichannel applicator was also studied, and its dosi-
metric advantages were demonstrated using planning 
data in two studies with twelve patients in both investi-
gations [14,15]. For other sites, information about inverse 
planning in BT is sparsely available. In a case study with 
two patients, Jameson et al. [16] presented the usefulness 
of IPSA for head and neck BT, and Choi et al. [17] com-
pared two inverse algorithms (IPSA, HIPO) in interstitial 
tongue HDR-BT of 20 patients. Regarding breast cancer, 
two inverse planning algorithms (IPSA, HIPO) were 
compared for 20 patients treated with BT boost using rig-
id needles [32]. With IPSA algorithm, the dose to OARs 
was less, but the target coverage and conformality was 
better with HIPO. In a recent paper, simulated annealing 
optimization was demonstrated for permanent breast im-
plant treatment planning [33]. Treatment plans produced 
manually and with inverse planning of a 10-patient co-
hort were dosimetrically compared. Although in target 
coverage and dose to skin, no difference was found, a sta-
tistical difference was observed in reduction of volume 
irradiated by the 1.5 times the PD and in increase of con-
formity index in favor of inverse planning. 
To the best of our knowledge, in interstitial HDR 
breast BT, detailed investigation of the input parameters 
of inverse optimization algorithms on dosimetry has not 
been performed. In our study, using HIPO, we firstly 
analyzed the effect of weight factors on target dose pa-
rameters accountable for target coverage (MinWeight), 
and dose homogeneity (MaxWeight) on quality of dose 
distributions in a breast implant. We clearly showed that 
these two factors played against each other. In order to 
find an acceptable compromise between the coverage and 
the homogeneity, we changed those weight factors step-
by-step and subsequently determined a recommended 
range of their values. Dosimetric constraints for normal 
tissues surrounding the PTV had an influence on both the 
coverage and the homogeneity. To investigate this phe-
nomenon, we changed the maximum dose (MaxValue 
between 20-120%) and its weight (MaxWeight between 
5-100) to normal tissue and calculated the V100 and the 
DNR. According to data in Table 1, the weight factor has 
a role only when the prescribed maximum dose in normal 
tissue is low (≤ 100%). If the MaxValue is 120, the V100 is 
always larger than 90%, independently on the weight fac-
tor. At low maximum doses (MaxValue ≤ 60%), the dose 
distribution is always homogeneous with low DNR, and 
the weight factor does not have a big effect (Table 2). But, 
at low weight factor (MaxWeight = 5), the DNR is prac-
tically the same (0.30-0.31) at any maximum dose value. 
The skin is considered as one of the most important 
OARs in breast BT. Similarly, to normal tissue, a maxi-
mum dose and its weight factor are the input parame-
ters for skin dosimetry in inverse planning. Logically, 
with these two parameters, the dose to skin can be sim-
ply controlled. But, at the same time, the target coverage 
and the dose homogeneity are changing as well. If the 
skin is far from the PTV, there is no reason to use dose 
constraints, since it always receives relatively low dose. 
However, when the PTV is in close proximity to the skin, 
dose objectives in order to decrease the maximum dose 
can be applied. It is evident that the smaller the distance 
between the skin and PTV, the higher the maximum dose 
to skin. We investigated the role of input parameters of 
optimization for skin when the PTV is in contact with 
skin. Tables 3 and 4 demonstrate how the V100 and DNR 
are affected by the values of MaxWeight and MaxValue. 
Summarizing the results obtained with optimization of 
dose to skin, we can state that, basically, there is no effect 
of dose objectives for skin on the target coverage and the 
dose homogeneity. The explanation can be that the opti-
mization objectives for normal tissue are strong enough 
to control the dose distribution outside the PTV. In fact, 
if it is not outlined separately, the skin is a part of normal 
tissue and if similar dose constraints are used as for the 
normal tissue, their effects will be minimal. Considering 
that the positions of the ribs related to the PTV can be 
very similar to the skin (far from or close to it), the con-
clusions drawn for skin dosimetry are valid for the ribs as 
well. We recommend using optimization parameters for 
any OAR only in a special case, when the maximum dose 
has to be kept below a certain level. Nevertheless, it must 
not be forgotten that dose to any OAR cannot be reduced 
unless the dose delivered to the PTV is decreased. 
The classical dosimetry systems are based on LDR 
sources. With the stepping source technique, those sys-
tems can be simulated using uniform source dwell times 
[2,3,34]. However, after any optimization technique, 
the dwell times will be non-uniform, occasionally with 
large fluctuation. The dwell time gradient restriction in 
HDR stepping source dosimetry was introduced to avoid 
large dwell time differences in adjacent source dwell po-
sitions [35]. The role of controlling neighboring dwell 
times in quality of treatment plan is controversial. In 
a recent study, a negative correlation was found between 
modulation restriction, and both HR-CTV D90 and V100 in 
cervix BT as well as an increasing restriction, negatively 
affected the conformity index [36]. According to the re-
sults of Mavroidis et al. [37], dwell time regularization 
technique in HIPO introduced a minor improvement in 
the effectiveness of the optimized prostate HDR dose dis-
tributions. Balvert et al. [38] also investigated the role of 
dwell time modulation restrictions for HDR prostate BT 
and found that the use of restriction did not necessarily 
improve the treatment plan quality. In another study, an 
increase of dwell time deviation constraint yielded a few 
percent decrease in target coverage and a slight increase 
in V150 in HDR prostate implants using IPSA [39]. The lat-
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ter is in agreement with our results shown in Table 5. The 
most homogeneous dose distribution develops when no 
restriction is used for the gradient, and the DNR is con-
tinuously increasing with stronger restriction. However, 
the difference between the extreme DNR values is only 
5%, while the value of V100 practically does not change. 
Although our detailed investigation about the role 
of input parameters on plan quality in inverse planning 
was performed only in one selected case, the results were 
validated in a relatively large patient cohort of forty-two 
cases. Our data showed that inverse planning performs 
better than forward planning regarding dosimetric pa-
rameters of target and OARs. In interstitial breast im-
plants, a large number of dwell positions are in the tar-
get volume, which probably contributes to the efficacy of 
optimization algorithm. In other treatment sites such as 
cervix or head and neck, much less dwell positions are 
used, and the advantages of inverse planning may not 
be so evident. Though quantitative data about planning 
time was not given here, we noted that inverse planning 
requires considerably less amount of time than forward 
planning. This is another point for implementing inverse 
planning in clinical practice. 
Conclusions 
Prerequisite for effective use of inverse planning al-
gorithm in interstitial breast BT is the determination 
of proper input parameters for optimization. Having 
found those presets, the optimization procedure is fast 
and practically always resulting in more superior dose 
distribution, when compared with forward planning. 
This statement was verified by comparing the data of 
patients’ dosimetry obtained by the two optimization 
methods. Our results clearly show that inverse planning 
is superior to forward planning, since at the same target 
coverage, all dosimetric parameters for any OAR, except 
only for contralateral lung, were more favorable with in-
verse planning, and in most cases, the differences were 
statistical significant. Furthermore, more homogeneous 
and more conformal dose distributions developed after 
inverse planning. Based on our results, the introduction 
of inverse planning into routine clinical practice is recom-
mended in interstitial HDR breast brachytherapy. 
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